-
This is from Dr. Alan Green's https://rapamycintherapy.com/ :
"Researchers used a mouse model of AD called 5XFAD. This model overproduces massive amounts of amyloid. The mouse has 5 defective genes from autosomal dominant familial AD. Rapamycin decreases the activity of the innate immune system which includes macrophages and microglia. Therefore, rapamycin naturally decreases the clearance of amyloid in this mouse model. Rapamycin is not good for this mouse.
99.9% of AD cases do not have these defective genes.
This 5XFAD mouse model is not applicable to most humans and in particular humans at increased risk due to being APOE4 carriers.
In my opinion, the finding in this study is only applicable to the 0.1% of AD cases that are familial autosomal dominant."